Micronized substances, i.e., powdered products with the distribution of particles of the size in the range 1 to 10 μm find nowadays a variety of applications. However, in all cases, there are substantial technical issues related to the degree of their easiness to be handled and exact control of dosing due to the high tendency of individual particles to further agglomerate, because their automatic adhesion forces, here mainly the Van-der-Waals forces, considerably exceed the force of gravity exerted on them.
Micronization of powders occupies an important place in the field of inhalative application of active pharmaceutical ingredients, because in order to ensure sufficient pulmonary availability, the relevant particles must have a diameter of approximately 1 to 5 μm. Especially in this area, a precise dosage of often very small volumes plays an important role. A common method to achieve the requisite sufficient flowability of preparation is the production of so-called interactive powder mixtures, i.e., the conscious binding of micronized active particles to an inert carrier. In most cases, this is performed using lactose particles in a particle size range from 50 to 200 μm, whereby the obtained active substance mixture in comparison to the pure micronized active substance possesses a significantly improved fluidity. Using suitable powder inhalers, by targeted air turbulence within the device, the active substance is again separated from the carrier and can thus be inhaled when the carrier remains in the device itself and/or in the mouth or pharyngeal cavity of the user. With this design however, the tendency to bond between the active substance and the carrier is so high that a large part of the active particle remains bound to the carrier, and therefore (depending on the particular type) remains unused in the powder inhaler or is swallowed by the user rather than to reach the lungs as is desired.
In the search for alternatives to interactive powder mixture, it turned out that the selective agglomeration of micronized active ingredients can provide an alternative to interactive powder mixture with carrier particles. This process includes the production of spherical agglomerates (pellets) of pure active substance particle or with the addition of some micronized excipient that is stable enough to allow the technical handling, but unstable enough to allow in turn a pulmonary delivery by re-dispersion in a suitable powder inhaler according.
The patent SE19930003214 19,931,001 describes the preparation of such an agglomerate referred to as “soft pellets”, where starting pellets are produced by forcing micronized powder through a sieve. The powder is here supplied with a screw conveyor and the generated starting pellets are rounded, in batches, in a rotating pan and then sorted through a sieve to obtain the percentage of pellets of a predetermined size range.
In contrast, the device of the invention and the invented method are based on a completely different type of rounding. Instead of the batch-wise production in small quantities (up to 500 g) in a rotating vessel, the invented device and method use for this purpose a vibrating surface.
Advantages can be seen here:
In addition, in terms of their hardness or breaking strength, the pellets as described in SE19930003214 19931001 are within a range from 0.5 to 100 nm. In contrast, the invented device and the method of the invention allow the production of spherical pellets with a hardness and fracture resistance of less than 0.5 nm.
The method as described in SE19930003214 19931001 can also be found, in an exact or similar form, in the following patents: GB20000012261 20000519; GB 19940004945 19940315; SE19970000133 19970120; SE19970000134 19970120; SE19970000135 19970120; SE19970000136 19970120 so that all of them substantially differ from that described by our invention.
The patent CH19900000266 19900129 describes a device and a method for dosing small amounts of poorly flowing powders.
In contrast to this, the invented device and the method of the invention focus not on the filling or the dosing, but rather on the production of targeted rounded powder agglomerates or pellets. Moreover, in the present invention, the goal is especially the clear spherical morphology of the resulting powder agglomerates.
In addition, the CH19900000266 19900129 concerns merely a formoterol-lactose mixture and does not disclose the universal nature of the invention and the inventive device.
A number of other patents also deal with the filling and transportation of (partially agglomerated) substances. They all significantly differ from the present invention, because essentially the transportation dosing requires a completely different kind of construction of the device and (if they apply vibration or oscillation), they have different frequency ranges.
Specifically, these are:
The GB19950015340 19950726 describes the dispensing of powders, where the volume to be filled is achieved using a vibrating feed hopper working in the frequency range of 1 to 1000 Hz. In contrast to the invented method and the device of the invention, apart from the similar frequency range there exist no matches.
The US20030434009 2003050 describes an apparatus for dispensing (dosing) powders, in which the filling process is allowed or supported by a vibration of the hopper in the frequency range of 10 to 1,000,000 Hz. It is mentioned explicitly that, in this case, a powder flow without any aggregation, i.e., agglomeration is to be generated.
The US19970100437P 19970721 relates to the transport of powders, where powder-transporting parts oscillate vertically in the frequency range from 1000 to 180,000 Hz and horizontally, in the frequency range from 50 to 50,000 Hz.
The US19960638515 1996042 is limited to the transport and a subsequent dosing of powders. The device has one or two screens. These screens oscillate at a frequency in the range of 1 to 500 Hz. No value whatsoever is placed on the morphology of the thus produced agglomerates. Furthermore, it is only assumed that only an undefined mixture of small agglomerates and individual particles is generated.
The US19850713697 19850319 describes a device that should allow the transport and subsequent dosing of powders, wherein the powder flow should be ensured by means of a vibrating transportation surface. There is no attention given to the emerging powder agglomerates and their morphology.
The SE20040000282 20040209 relates to the measurement and filling of powders. Oscillation in the form of ultrasonic vibrations or similar vibration is used here only in support of the filling process.
The technical task that underlies the present invention is to provide a new method and a new device for a continuous production of spherical powder agglomerates or pellets, which overcome the disadvantages of the prior art.
This technical task is resolved by a method according to claim 1 and a device according to claim 10.
Preferred embodiments are the subject of the dependant claims.
The present invention is represented by an apparatus and a method for a continuous production of spherical powder agglomerates (pellets). The expected properties of the resulting spherical agglomerates (pellets) should include a nearly perfect roundness, so the best possible flow, consequently, a good ability to be dispensed in accurate dosage, sufficient stability for the technical handling and, finally, a satisfactory ability to be re-dispersed in pulmonary application.
For this purpose, the powder to be treated, whose individual particles are preferably micronized, i.e., they are present with an average diameter of 5 μm, is formed by forcing it through a sieve or sieve-similar device to become morphologically heterogeneous starting pellets [
A design illustrated in
At the bottom of the device [
Using a combination of a control unit [i] and a computer [j], the fixed-frequency generators [
Micronized disodium cromoglycate (DSCG) is agglomerated by forcing it through a sieve with a mesh size of 355 μm. Scanning electron micrographs of these starting pellets are shown in [
2. Micronized disodium cromoglycate (DSCG) is treated as described in Example 1, with the difference that the resulting spherical pellets are placed on the metal foil, which oscillates a frequency of 100 Hz, two more times; thus they travel the threefold distance on the foil. As expected, this results in an even more rounded shape, with a length ratio of the resulting pellets of 1.15, with a roundness of 88.6 or roughness of 1.016. A detailed aerodynamic characterization also reveals an influence of the changes in experimental conditions such that the share available for pulmonary delivery slightly decreases, but continues to remain within a very satisfactory range.
3. Micronized disodium cromoglycate (DSCG) is treated as described in Example 1, with the difference that the metal foil of the device oscillates at a frequency of 50 Hz. The result is in a comparable range, whereas the quality, as for roundness and the roughness slightly decreases, however, for the benefit of improved redispersibility, and therefore improved pulmonary availability in the aerodynamic characterization.
4. Micronized disodium cromoglycate (DSCG) is treated as described in Example 1, with the difference that the metal foil does not constantly oscillate with a frequency of 100
Hz throughout the manufacturing process, but the frequency is modulated. More specifically, this means that the frequency goes through a range of 100 to 20 Hz over a period of one second in increments of 1 Hz. After a second, the frequency jumps immediately back from 20 Hz to 100 Hz, and in the period of the next second it again reaches 20 Hz in steps of 1 Hz. This variant of the method provides also results comparable with the other examples.
5. Micronized budesonide is treated similarly to that described in Example 1 with comparable results.
6. Micronized fluticasone propionate is treated in a fashion similar to that described in Example 1 with comparable results.
7. Micronized salbutamol sulphate is treated similarly as described in Example 1 with comparable results.
8. A mixture of micronized formoterol fumarate and lactose in the ratio 1:50 is treated similarly to that described in Example 1 with comparable results.
9. A mixture of micronized budesonide, formoterol fumarate and micronized lactose in the ratio 2:1:50 is treated similarly to that described in Example 1 with comparable results.
10. A mixture of micronized fluticasone propionate, micronized salmeterol xinafoate and lactose in the ratio 2:1:50 is treated in a fashion similar to that described in Example 1 with comparable results.
11. Pharmacologically largely inert substances may also be treated as described in Example 1. Here, the point is logically not to achieve a good pulmonary availability, but rather to improve the manageability and controllability of these substances. Consequently, lactose treated in a fashion similar to that in Example 1 also provides spherical pellets that meet the above criteria.
12. Analogously to Example 10, one obtains comparable results in the treatment of mannitol.
The figures show:
Number | Date | Country | Kind |
---|---|---|---|
10 2007 049 931.2 | Oct 2007 | DE | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/EP2008/008655 | 10/13/2008 | WO | 00 | 9/21/2010 |